arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

ROCKET PHARMACEUTICALS, INC.

RCKT

$3.52 ▲ +0.03 (+0.86%) at close

13 Visible periods

22 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

ROCKET PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $391.2M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -83.6% ↘

FCF / Share $-1.71 ↗

Trailing P/E —

Price / Book 1.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

13-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-223.12M

↑ +13.8% —

FCF / Share Free cash flow per share

$-1.71

↑ +24.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
EPS Growth YoY (%)	26.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	6.5% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	10.4% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-22.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-6.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	13.8% Fair ↑ Fair Improving Year-over-year change in net income	-5.4% Weak ↑ Weak Improving Year-over-year change in net income	-10.7% Weak ↑ Weak Improving Year-over-year change in net income	-31.2% Weak ↑ Weak Improving Year-over-year change in net income	-21.0% Weak ↑ Weak Improving Year-over-year change in net income	-80.8% Weak ↓ Weak Declining Year-over-year change in net income	-3.7% Weak ↑ Weak Improving Year-over-year change in net income	-280.6% Weak ↓ Weak Declining Year-over-year change in net income	54.3% Excellent ↑ Excellent Improving Year-over-year change in net income	37.0% Excellent Excellent Year-over-year change in net income	-613.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	24.6% Good ↑ Good Improving Year-over-year change in free cash flow	9.6% Fair ↑ Fair Improving Year-over-year change in free cash flow	8.1% Fair ↑ Fair Improving Year-over-year change in free cash flow	-34.4% Weak Weak Year-over-year change in free cash flow	-18.4% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	0.85x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.14x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Return on Invested Capital (%)	-83.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-59.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-41.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-36.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-29.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-21.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-19.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-29.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-100.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-45.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-14.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	11.8% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-70.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-51.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-45.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-40.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-33.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-22.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-20.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-28.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-98.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-32.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-18.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-139.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-80.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-637%)	-55.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-472%)	-49.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-432%)	-45.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-402%)	-37.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-348%)	-27.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-285%)	-25.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-268%)	-38.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-356%)	-126.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-941%)	-58.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-490%)	-62.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-517%)	18.5% Good Good Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+23%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Interest Coverage (x)	-122.55x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-144.86x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-138.48x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-120.48x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-56.18x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-19.28x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-12.78x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-11.78x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	—	-29.53x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-16.58x Weak Weak Operating income divided by interest expense Optimal: > 5x	-7.86x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-77.56M	$-163.63M	$-55.90M	$-140.52M	$-232.69M	$-297.10M	$-185.38M	$-111.36M	$-18.14M	$-29.80M	$-80.04M	$-3.62M	$-12.79M

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Revenue per Share (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-2.01	$-2.73	$-2.92	$-3.26	$-2.67	$-2.52	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-1.71	$-2.27	$-2.52	$-2.74	$-2.04	$-1.72	—	—	—	—	—	—	—
Book Value per Share (USD)	$2.56	$4.35	$5.46	$6.19	$7.05	$8.25	$5.61	$4.30	$2.28	$10.85	$4.12	$-50.54	—
Tangible Book Value per Share (USD)	$1.97	$3.75	$4.74	$5.37	$6.57	$7.75	$5.05	$3.62	$2.28	$10.85	$4.12	$-50.54	—
Basic Weighted Avg Shares (shares)	111.12M	94.81M	84.01M	68.15M	63.24M	55.38M	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Working Capital (USD)	$162.53M	$337.50M	$329.72M	$324.89M	$369.89M	$454.73M	$289.44M	$193.72M	$14.43M	$121.31M	$108.22M	$-3.55M	—
Total Equity (USD)	$277.22M	$463.23M	$492.57M	$489.69M	$454.72M	$503.52M	$307.30M	$194.04M	$15.52M	$73.17M	$108.81M	$-51.56M	$-38.90M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	—	—	—	—
Depreciation Expense (USD)	$8.90M	$7.20M	$4.90M	$3.90M	—	—	$426.00K	$330.00K	$204.00K	$169.00K	$45.00K	$0.00	—
Net Income, GAAP (USD)	$-223.12M	$-258.75M	$-245.59M	$-221.86M	$-169.07M	$-139.70M	$-77.27M	$-74.52M	$-19.58M	$-42.85M	$-67.98M	$-9.53M	—
Operating Cash Flow (USD)	$-190.01M	$-209.72M	$-194.92M	$-178.14M	$-121.16M	$-74.64M	$-64.66M	$-53.79M	$-15.96M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 50 quarters

ROCKET PHARMACEUTICALS, INC.

Analytical Summary

13-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare RCKT with peers